We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

Back to rankings

1 hedge funds and large institutions have $34.3M invested in Ariad Pharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 191 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% less funds holding in top 10

Funds holding in top 10: 9 → 1 (-8)

98% less capital invested

Capital invested by funds: $2.13B → $34.3M (-$2.09B)

99% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 191

100% less funds holding

Funds holding: 200 → 1 (-199)

Holders
1
Holders Change
-199
Holders Change %
-99.5%
% of All Funds
0.02%
Holding in Top 10
1
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-88.89%
% of All Funds
0.02%
New
1
Increased
–
Reduced
–
Closed
191
Calls
$31K
Puts
–
Net Calls
+$31K
Net Calls Change
+$16.5M

Top Buyers

Rank Fund Capital Flow
1
FPF
FNY Partners Fund
New York
+$32M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$225M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$218M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$182M
4
SCM
Sarissa Capital Management
Connecticut
-$160M
5
State Street
State Street
Massachusetts
-$97.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
FPF
1
FNY Partners Fund
New York
$34.3M +$32M +1,428,547 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
– -$225M -18,126,264 Closed
Wellington Management Group
3
Wellington Management Group
Massachusetts
– -$218M -17,521,066 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$182M -14,591,103 Closed
SCM
5
Sarissa Capital Management
Connecticut
– -$160M -12,850,000 Closed
State Street
6
State Street
Massachusetts
– -$97.9M -7,869,172 Closed
PI
7
Putnam Investments
Massachusetts
– -$97.3M -7,822,704 Closed
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
– -$67.8M -5,451,998 Closed
Westfield Capital Management
9
Westfield Capital Management
Massachusetts
– -$61.7M -4,957,058 Closed
PC
10
PointState Capital
New York
– -$61.5M -4,946,800 Closed
RG
11
Redmile Group
California
– -$47.7M -3,838,376 Closed
CCM
12
Consonance Capital Management
New York
– -$44.2M -3,553,943 Closed
AllianceBernstein
13
AllianceBernstein
Tennessee
– -$43.7M -3,512,570 Closed
PAI
14
Palo Alto Investors
California
– -$33.4M -2,682,017 Closed
Norges Bank
15
Norges Bank
Norway
– -$29.1M -2,339,750 Closed
TCM
16
TimesSquare Capital Management
New York
– -$27.8M -2,237,365 Closed
Northern Trust
17
Northern Trust
Illinois
– -$26M -2,093,677 Closed
O
18
OppenheimerFunds
New York
– -$23.3M -1,870,370 Closed
Two Sigma Investments
19
Two Sigma Investments
New York
– -$22.8M -1,834,011 Closed
Lord, Abbett & Co
20
Lord, Abbett & Co
New Jersey
– -$22.3M -1,792,326 Closed
Jennison Associates
21
Jennison Associates
New York
– -$20.7M -1,660,288 Closed
Geode Capital Management
22
Geode Capital Management
Massachusetts
– -$19.1M -1,534,851 Closed
PAMU
23
Pictet Asset Management (UK)
United Kingdom
– -$18.9M -1,515,257 Closed
Ameriprise
24
Ameriprise
Minnesota
– -$17.9M -1,439,502 Closed
Goldman Sachs
25
Goldman Sachs
New York
– -$17.3M -1,394,100 Closed
1
2 3 4 5

ARIA Hedge Fund Activity: Q1 2017 in Review

1 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q1 2017, worth a combined $34.3M — down 98% from $2.13B a quarter earlier.

Sellers outnumbered buyers: 191 funds closed out of ARIA and 1 opened new positions — a net loss of 190 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was FNY Partners Fund, opening a new position worth an estimated $32M. The largest seller was Fidelity Investments, exiting entirely with an estimated $225M sold.

  • 1 institutional investor held Ariad Pharmaceuticals Inc (ARIA) as of Q1 2017, down from 200 in Q4 2016.
  • Funds reported $34.3M of Ariad Pharmaceuticals Inc stock for Q1 2017, down 98% quarter-over-quarter.
  • 1 fund opened new Ariad Pharmaceuticals Inc positions in Q1 2017 and 191 closed out, a net change of -190 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q1 2017 was FNY Partners Fund, an estimated $32M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q1 2017 was Fidelity Investments, an estimated $225M sold.

Based on aggregated 13F filings for Q1 2017.